Prognostic factors associated with 30-day in-hospital mortality in coagulase-negative Staphylococcus bacteraemia: no impact of vancomycin minimum inhibitory concentration

References

• Falcone M, Russo A, Venditti M. Optimizing antibiotic therapy of bacteremia and endocarditis due to staphylococci and enterococci: new insights and evidence from the literature. J Infect Chemother. 2015;21:330–339.
   PubMed Web of Science ®Google Scholar
• John JF, Harvin AM. History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents. Ther Clin Risk Manag. 2007;3:1143–1152.
   PubMedGoogle Scholar
• Paul M, Kariv G, Goldberg E, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2010;65:2658–2665.
   PubMed Web of Science ®Google Scholar
• N’Guyen Y, Baumard S, Vernet-Garnier V, et al. Coagulase-negative Staphylococcus bacteraemia accounts for one third of Staphylococcus bacteraemia in a French university hospital. Scand J Infect Dis. 2012;44:79–85.
   PubMed Web of Science ®Google Scholar
• Sharma M, Szpunar S, Khatib R. Validating severity of illness scoring systems in the prediction of outcomes in Staphylococcus aureus bacteremia. Am J Med Sci. 2013;346:87–91.
   PubMed Web of Science ®Google Scholar
• Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;15:193–200.
   Web of Science ®Google Scholar
• López-Cortés LE, Velasco C, Retamar P, et al. Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?. J Antimicrob Chemother. 2015;70:2652–2660.
   PubMed Web of Science ®Google Scholar
• Cervera C, Castañeda X, de la Maria CG, et al. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis. Clin Infect Dis. 2014;58:1668–1675.
   PubMed Web of Science ®Google Scholar
• N’Guyen Y, Baumard S, Vernet-Garnier V, et al. Addendum to: coagulase-negative Staphylococcus bacteraemia accounts for one third of Staphylococcus bacteraemia in a French university hospital. Scand J Infect Dis. 2012;44:555.
   PubMed Web of Science ®Google Scholar
• Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006;1:S13–S24.
   Web of Science ®Google Scholar
• García de la Mària C, Cervera C, Pericàs JM, et al. Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration. PLoS One. 2015;10:e0125818.
   PubMed Web of Science ®Google Scholar
• Valencia-Rey P, Weinberg J, Miller NS, et al. Coagulase-negative staphylococcal bloodstream infections: Does vancomycin remain appropriate empiric therapy? J Infect. 2015;71:53–60.
   PubMed Web of Science ®Google Scholar
• Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev. 2014;27:870–926.
   PubMed Web of Science ®Google Scholar
• von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis. 2002;2:677–685.
   PubMed Web of Science ®Google Scholar
• Coronado-Álvarez NM, Parra-Ruiz J. Vancomycin does not remain appropriate empiric therapy in coagulase-negative staphylococcal bacteremia. J Infect. 2016;72:403–404.
   PubMed Web of Science ®Google Scholar
• Recommendations of the Antibiogram Committee of the French Microbiology Society (CA-SFM) [Internet]. 2012. [cited 2016 Sept 19]; Available from: http://www.sfm-microbiologie.org/UserFiles/files/casfm/CASFM_2012.pdf.
   Google Scholar
• Burton DC, Edwards JR, Horan TC, et al. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997–2007. JAMA. 2009;18:727–736.
   Google Scholar
• Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29:530–538.
   PubMedGoogle Scholar
• Lesens O, Methlin C, Hansmann Y, et al. Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity. Infect Control Hosp Epidemiol. 2003;24:890–896.
   PubMed Web of Science ®Google Scholar
• Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;1:1–45.
   Web of Science ®Google Scholar
• Lesens O, Hansmann Y, Brannigan E, et al. Healthcare-associated Staphylococcus aureus bacteremia and the risk for methicillin resistance: is the Centers for Disease Control and Prevention definition for community-acquired bacteremia still appropriate? Infect Control Hosp Epidemiol. 2005;26:204–209.
   PubMed Web of Science ®Google Scholar
• Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633–638.
   PubMed Web of Science ®Google Scholar
• Bellomo R, Ronco C, Kellum JA, etet al. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204–R212.
   PubMed Web of Science ®Google Scholar
• Park SY, Kwon KH, Chung J-W, et al. Coagulase-negative staphylococcal bacteremia: risk factors for mortality and impact of initial appropriate antimicrobial therapy on outcome. Eur J Clin Microbiol Infect Dis. 2015;34:1395–1401.
   PubMed Web of Science ®Google Scholar
• Raad I, Kassar R, Ghannam D, et al. Management of the catheter in documented catheter-related coagulase-negative staphylococcal bacteremia: remove or retain? Clin Infect Dis. 2009;15:1187–1194.
   Web of Science ®Google Scholar
• Molina J, Peñuela I, Lepe JA, et al. Mortality and hospital stay related to coagulase-negative Staphylococci bacteremia in non-critical patients. J Infect. 2013;66:155–162.
   PubMed Web of Science ®Google Scholar
• Topeli A, Unal S, Hayran M, et al. Septic shock as a predictor of mortality in bacteremia caused by coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis. 1997;16:411–416.
   PubMed Web of Science ®Google Scholar
• Finkelstein R, Fusman R, Oren I, et al. Clinical and epidemiologic significance of coagulase-negative staphylococci bacteremia in a tertiary care university Israeli hospital. Am J Infect Control. 2002;30:21–25.
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Tumbarello M, Donati KG, et al. Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case-control study. Clin Infect Dis. 2001;15:1628–1635.
   Web of Science ®Google Scholar
• Ahlstrand E, Svensson K, Persson L, et al. Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades. Eur J Clin Microbiol Infect Dis. 2011;30:1349–1354.
   PubMed Web of Science ®Google Scholar
• Paiva RM, Mombach Pinheiro Machado AB, Zavascki AP, et al. Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods. J Clin Microbiol. 2010;48:4652–4654.
   PubMed Web of Science ®Google Scholar
• Hsu DI, Hidayat LK, Quist R, et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents. 2008;32:378–385.
   PubMed Web of Science ®Google Scholar
• Dahmash NS, Chowdhury MN, Fayed DF. Coagulase-negative staphylococcal bacteraemia with special reference to septic shock: experience in an intensive care unit. J Infect. 1994;29:295–303.
   PubMed Web of Science ®Google Scholar
• Martin MA, Pfaller MA, Wenzel RP. Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay. Ann Intern Med. 1989;110:9–16.
   PubMed Web of Science ®Google Scholar
• Song KH, Kim M, Kim CJ, et al. Impact of vancomycin MIC on treatment outcomes in invasive Staphylococcus aureus infections. Antimicrob Agents Chemother. 2017;61:pii: e01845-16.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Van Schooneveld TC, Fey PD, et al. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. Jama. 2014;312:1552–1564.
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Fowler VG. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:S386–S393.
   PubMed Web of Science ®Google Scholar
• de Silva GDI, Kantzanou M, Justice A, et al. The ica operon and biofilm production in coagulase-negative Staphylococci associated with carriage and disease in a neonatal intensive care unit. J Clin Microbiol. 2002;40:382–388.
   PubMed Web of Science ®Google Scholar